Veracyte Q3 EPS Tops by 59.4% with $131.8M Revenues
Veracyte reported third-quarter 2025 adjusted EPS of $0.51, outpacing consensus by 59.4%, with revenues of $131.8 million beating estimates by 5.5%. The company forecasts a 3% earnings recession rate for 2026 versus a 16.8% industry rise and has delivered four straight quarters of average 45% positive surprises.
1. Third-Quarter 2025 Results
Veracyte delivered adjusted EPS of $0.51 in Q3 2025, exceeding the consensus by 59.4%, while generating revenues of $131.8 million, a 5.5% surplus over estimates. This performance reflects strong demand across its core diagnostic offerings.
2. Trends in Earnings Surprises
This marked the fourth consecutive quarter of earnings beats for Veracyte, with an average surprise of 45.1%, underlining consistent outperformance against analyst projections.
3. 2026 Outlook and Earnings Recession
Veracyte projects a 3% earnings recession rate for fiscal 2026, substantially below the industry average of 16.8%, suggesting resilience in its business model despite broader sector headwinds.
4. Analyst Ranking and Market Position
Veracyte maintains a top-tier analyst ranking and is recognized for its leadership in molecular diagnostics, with recent financial results reinforcing its position among high-growth peers.